Dyne Therapeutics, Inc. (DYN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$19.19-5.51%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Dyne plans to launch z-rostudirsen for Duchenne Muscular Dystrophy in Q1 2027. The company also aims to launch z-basivarsen in Q1 2028. It has about $1.1 billion to fund operations into early 2028. Recent trial enrollments and regulatory milestones support these goals.
Dyne is still loss-making with negative cash flow. Launches depend on regulatory approval, which is uncertain. Delays or failures in trials could hurt the company’s future.
The stock trades about 37% below our fair value near $36. The market prices in risks from ongoing losses and uncertain approvals. Our fair value matches the Street median, so we weigh the full range of analyst views.
Breaks if: Cash falls below $1 billion before Q1 2028
Maintain sufficient cash, cash equivalents and marketable securities to fund operations through the second quarter of 2028.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown volatility in management execution, which adds uncertainty to its future performance.
The market appears to have low expectations for DYN, given its recent earnings miss and weak financial performance compared to peers. There is a low fragility tier, indicating that the current valuation does not reflect significant risk factors.
Management's priorities include launching new products and maintaining liquidity, but the recent financial performance has been weak. There is a low probability of missing estimates in the near term, although the company operates in a high-miss-rate industry.
The thesis hinges on the company's ability to successfully launch new products and manage its operations while navigating potential sector momentum. Key triggers include guidance cuts and economic conditions affecting the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations, contributing to a sharp drop. This drop suggests the market is repricing the reasons to own DYN. Additionally, risks in the clinical pipeline, including the impact of a rival drug's trial failure, further threaten the outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. Cash, cash equivalents and marketable securities were $972.2 million at 2026-Q1 and $898.5 million at 2026-Q2. The company completed a public offering in July 2026 with net proceeds of approximately $405 million, supporting funding operations into Q2 2028. The trajectory shows the company maintaining sufficient liquidity consistent with management's stated funding horizon.
“Cash position plus July 2026 offering proceeds sufficient to fund operations into Q2 2028.”
“Cash, cash equivalents and marketable securities as of March 31, 2026, sufficient to fund operations into Q1 2028.”
“Cash expected to fund operations into the third quarter of 2027.”
“Cash expected to fund operations into the first quarter of 2028.”
Breaks if: Launch delayed beyond Q1 2028
Complete clinical trials and regulatory submissions to support a potential U.S. launch of z-basivarsen for myotonic dystrophy type 1 in early 2028.
Stated as a priority in 3 of last 3 quarters. Dyne completed enrollment in the ACHIEVE registrational expansion cohort with topline data expected in Q1 2027 to support a potential BLA submission in Q3 2027. Management expects a potential U.S. launch of z-basivarsen in early 2028, assuming FDA approval on the anticipated timeline. The trajectory shows continued clinical progress and regulatory planning.
“Topline data from ACHIEVE REC planned for Q1 2027 to support potential BLA submission for U.S. Accelerated Approval in Q3 2027.”
“Dyne expects a potential U.S. launch of z-basivarsen in Q1 2028, assuming FDA grants Priority Review and approval is received on the anticipated timeline.”
“Dyne continues to expect a potential U.S. launch of z-basivarsen in Q1 2028.”
Breaks if: Launch delayed beyond Q1 2027
Advance z-rostudirsen through FDA review and prepare for potential U.S. launch in Q1 2027 for Duchenne muscular dystrophy patients amenable to exon 51 skipping.
Stated as a priority in 3 of last 3 quarters. The FDA accepted Dyne's BLA for z-rostudirsen with Priority Review and a PDUFA target date of January 21, 2027. Management continues to expect a potential U.S. launch in Q1 2027, assuming approval on the anticipated timeline. The trajectory is delivering as the company progresses through regulatory milestones and prepares for commercial launch.
“FDA’s acceptance of our BLA for z-rostudirsen marks an important milestone... potential U.S. launch in Q1 2027.”
“On track to submit BLA in Q2 2026 and potential launch in Q1 2027.”
“Dyne continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming FDA grants Priority Review.”
Over the next 1 to 3 years, DYN's performance will depend on its execution of product launches and overall market conditions. Not investment advice.